The new London site was officially opened by David Willetts, Minister for Universities and Science. The decision to relocate its UK headquarters was taken due to significant expansion with the success of its multiple myeloma treatment Revlimid® (lenalidomide) and treatment for myelodysplastic syndromes, Vidaza® (azacitidine), as well as the recent acquisition of Abraxane®(nab™-paclitaxel) for metastatic breast cancer.Celgene is a global leader in haematology and has developed investigational compounds to treat haematological and solid tumour cancers, myelodysplastic syndromes, chronic lymphocyte leukaemia, non-Hodgkin's lymphoma, glioblastoma, and ovarian, pancreatic and prostate cancer.
“The Government is committed to making Britain the best place in the world to do business”, says David Willetts. “Celgene’s expansion is a vote of confidence in the UK pharmaceutical industry and shows the ability of our life sciences sector to drive growth and create jobs.”
Celgene is committed to making more potentially life-saving treatments a reality for the millions of patients around the world fighting rare and debilitating diseases. The company invests 30 per cent of its income in research and development into therapies that target the source of the disease, not the symptoms. Celgene has an extensive pipeline of high-potential compounds to address high unmet medical needs for years to come.
Sam Pearce, General Manager, UK and Ireland says; “The launch of our new UK headquarters today is another step in Celgene’s continued expansion in the UK. We are a company that is founded on innovation and at the core of our business is the passion to develop life-changing clinical advances in disease areas which have been overlooked or where the biggest unmet need exists. We hope that our continued focus on scientific excellence combined with our long term investment in research will make a significant difference to patients’ lives.”
There are more than 300 clinical trials at major medical centres using compounds from Celgene. Investigational compounds are being studied for patients with incurable haematological and solid tumour cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukaemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, and prostate, lung and pancreatic cancer.